Biotech & Health Tech PR: Communicating Science to Media and Investors

A biotech press release gets read by two very different audiences at the same time. A health reporter wants to know what a Phase 2 readout means for patients. An institutional analyst wants to know what it means for the stock. Both are reading the same 400 words — and both need an accurate, defensible understanding of the data.

That dual audience, plus a regulatory calendar that can move a company’s valuation on a single FDA letter, is what separates biotech and health tech PR from healthcare PR in general.

What is biotech and health tech PR? Biotech and health tech PR communicates clinical, scientific, and regulatory developments accurately to press, physicians, patients, and institutional investors simultaneously. It requires translating trial data and FDA milestones into language that survives scientific scrutiny and remains clear enough for a generalist reporter or portfolio manager.

How this differs from general healthcare PR

Virgo’s healthcare PR covers hospital systems, insurers, consumer health brands. Biotech PR is a narrower, higher-stakes slice. Companies are often pre-revenue or newly public, news moments are dictated by clinical trial phases and FDA decision dates, and the most important reader on any given day may be a sell-side analyst.

A framework for biotech communications

1. Translate the science — don’t simplify it into something wrong. Work directly from underlying data, not a marketing summary. Give journalists context alongside the topline number.

2. Map the regulatory calendar before you need it. IND filings, enrollment milestones, readouts, PDUFA dates, advisory committee meetings, approvals, complete response letters — all predictable in timing. Draft materials for both positive and negative scenarios.

3. Write for the analyst and the reporter in the same document, differently. Coordinate with investor relations from the start. See our investor relations PR guide.

4. Crisis plan before there’s a trial hold. Adverse events, clinical holds, missed endpoints — ordinary parts of development, emergencies if there’s no plan. Our crisis PR work covers this.

5. Scientific credibility as a media asset. Peer-reviewed publication, conference presentations, independent researcher citations — carry more weight than company claims. Time announcements around these credibility markers.

6. Health tech as a distinct sub-case. Digital health companies face different milestones: FDA clearance for SaMD, data privacy scrutiny, health system procurement cycles. Same discipline around accuracy, different set of milestones.

Where biotech PR stalls

Overstating early data. A positive trend in a small Phase 1 cohort is not a cure.

Treating investor and media messaging as separate tracks. When IR and PR work from different talking points, reporters and analysts notice the gap.

Skipping legal and medical review for speed. Creates more risk than the delay.

FAQ

What’s the difference between biotech PR and general healthcare PR? Biotech PR focuses on clinical-stage and scientific communications. General healthcare covers providers, payers, and consumer health brands.

How does PR work around FDA announcement dates? Build a communications calendar around known regulatory dates and prepare materials for multiple outcomes ahead of time.

When should an early-stage biotech start with PR? Build relationships with reporters and analysts well before the first major data readout — the first meaningful coverage often requires a fast, accurate response.

See our sector specialties, or read our investor relations guide if institutional investors are a primary audience.